Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04380324 · ClinicalTrials.gov registry record · Phase 1

A Study of NKTR-358 (LY3471851) in Healthy Participants

A Phase 1 study, sponsored by Nektar Therapeutics.

Completed
Registry status
Phase 1
Development phase
100
Enrollment target

NCT04380324 is a Phase 1 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04380324, a Phase 1 study, has completed, sponsored by Nektar Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
100 participants
Enrollment target

Study Summary

The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in healthy participants. The study will last about 50 days for each participant.

Interventions

  • DRUG Placebo
  • DRUG LY3471851

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2017-03-19
Est. Completion 2019-01-20
Phase Phase 1

Sponsor

Nektar Therapeutics

37 total trials

What the Registry Record Tells You About NCT04380324

The ClinicalTrials.gov registry entry for NCT04380324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT04380324 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04380324 about?

NCT04380324 is a clinical study titled "A Study of NKTR-358 (LY3471851) in Healthy Participants". The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in healthy participants. The study will last about 50 days for each participant.

What is the current status of trial NCT04380324?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2017-03-19. Estimated completion is 2019-01-20.

What interventions are being tested in trial NCT04380324?

The interventions under investigation include: Placebo (DRUG), LY3471851 (DRUG).

Who is sponsoring clinical trial NCT04380324?

This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.